Wild-Type Respiratory Syncytial Virus Type B (RSV-B)

Name: Wild-Type Respiratory Syncytial Virus Type B (RSV-B)
SKU: VNV-105

Cat.No. : VNV-105

Storage: -80°C Shipping: Dry ice

Inquire for Price

Product Infomation

Cat. No.	VNV-105
Description	These viruses are wild type respiratory syncytial virus type B (RSV-B) particles which are replication-competent. This product is intended for research use only.
Shipping	Dry ice
Storage	-80°C

Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots.
Mycoplasma	Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination.
Purity	Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards.
Sterility	The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination.
Transducibility	Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities.
Proviral Identity Confirmation	All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert.

Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Respiratory syncytial virus type B (RSV-B) is a highly contagious pathogen primarily transmitted through respiratory droplets, direct contact with infected individuals, or contaminated surfaces. The virus enters the host through the eyes, nose, or mouth and attacks the respiratory epithelial cells. RSV-B is a major cause of lower respiratory tract infections (LRTIs), particularly in infants, the elderly, and immunocompromised individuals, often leading to bronchiolitis or pneumonia. Its pathogenesis involves viral replication in respiratory epithelial cells, triggering an exaggerated immune response characterized by neutrophil infiltration, cytokine release (such as IL-6 and TNF-α), and excessive mucus secretion. This inflammatory cascade leads to airway obstruction and tissue damage. RSV-B peaks seasonally in temperate regions, typically in winter, where recurrent infection can occur due to incomplete immunity.

RSV-B belongs to the Pneumoviridae family and has a pleomorphic envelope approximately 150-250 nanometers in diameter. Its lipid bilayer is covered with three surface glycoproteins: attachment glycoprotein (G), fusion protein (F), and small hydrophobic protein (SH). The G protein mediates host cell binding, while the F protein facilitates viral entry by inducing membrane fusion. The RSV-B genome consists of a single-stranded negative-sense RNA (approximately 15.2 kb) encoding 11 proteins, including the nucleocapsid (N), phosphoprotein β, matrix protein (M), and RNA-dependent RNA polymerase (L). Unlike RSV-A, RSV-B exhibits genetic variation in the G protein (particularly its hypervariable region), which influences antigenic diversity and immune evasion. Its genome is tightly associated with the N protein, forming a ribonucleoprotein (RNP) complex that is essential for viral replication. Nonstructural proteins (NS1 and NS2) modulate the host interferon response and enhance viral persistence.

Since RSV fusion protein (F) is more conserved than glycoprotein (G) among RSV strains and serotypes, most candidate vaccines target viral fusion protein (F) rather than glycoprotein to induce a broader range of protective neutralizing antibodies. Here, researchers screened two chemically modified mRNA vaccines expressing RSV prefusion stabilizer protein (preF) targeting RSV A2 and B subtypes, respectively. Antigen-specific binding antibodies, neutralizing antibodies, and T cell-mediated immune responses were evaluated after immunization. The results showed that the mRNA candidate vaccine induced strong antigen-specific binding antibodies, neutralizing antibody responses, and Th1-biased T cell responses in both mice and cotton rats. In addition, cotton rats vaccinated with mRNA vaccines had significantly reduced lung pathology and infectious lung virus loads, and no vaccine-enhanced respiratory disease (VERD) occurred. Together, these results indicate that mRNA-based vaccines induce strong humoral and cellular immunity and provide excellent protection against RSV A2 and RSV B subtypes in rodents.

To further explore the immunogenicity of the vaccine in cotton rats, T2A-preF or IRES-preF mRNA vaccines (4 µg, 10 µg, or 25 µg) or FI-RSV were injected intramuscularly into cotton rats twice, 3 weeks apart. Each group of cotton rats was immunized intranasally once, with RSV A2 as a positive control and PBS as a negative control. Serum was collected at different time points after the second immunization, and the binding antibody titers against the prefusion F protein and the neutralizing antibody titers against RSV A2 or RSV B were tested by ELISA (Figure 1A). The results showed that all mRNA vaccines could induce increased levels of RSV F protein antibodies in serum and produce neutralizing antibody titers. Regardless of the dose, the antibody titers induced by the T2A-preF mRNA vaccine peaked on day 28 and decreased significantly on day 35, but were still higher than the antibody titers on day 21. The IRES-preF mRNA vaccine group also showed the same trend (Figure 1B). All mRNA vaccines induced significantly higher neutralizing antibody titers against RSV A2 or RSV B strains compared with FI-RSV, the naive, or RSV A2 groups. However, there was no dose dependence (Figure 1C). In addition, ELISpot results showed that IFN-γ secretion by spleen T lymphocytes in the 10 µg T2A-preF or 25 µg IRES-preF mRNA group was significantly higher than that in the naive or FI-RSV group, which was consistent with the observations in mice (Figure 1D). Together, these results indicate that RSV mRNA vaccines induced strong humoral and Th1-biased cellular immune responses in cotton rats.

Figure 1. Cotton rat immunogenicity. (Liu J, et al., 2025)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

First Name

Country *

Email *

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *